Research on Alzheimer's disease, from early signs to new therapies. Covers screening tools, brain damage mechanisms, risk factors, sleep, and drug targets.
A recent study suggests that the gut microbiome affects brain behavior, immune cells and neurodegeneration. Altering the gut microbiome could be an effective way to prevent or treat neurodegenerative diseases like Alzheimer’s.
A new twin study by Karolinska Institutet suggests that the same genes may be behind both cardiometabolic diseases and dementia. The study found that individuals with multiple cardiometabolic conditions had a significantly increased risk of developing dementia.
A new study reveals that falls are nearly 50% among older Americans with dementia, emphasizing the importance of addressing environmental and health-related risk factors. Key findings highlight the need for tailored screening and prevention interventions specifically designed for this high-risk population.
Research suggests that six minutes of high-intensity exercise can increase the production of brain-derived neurotrophic factor (BDNF), a protein essential for brain formation, learning, and memory. BDNF promotes neuroplasticity and neuronal survival, potentially delaying age-related cognitive decline.
A new study identifies a protein called GFAP as a possible biomarker for very early stages of Alzheimer's disease, which can be detected ten years before symptoms arise. This breakthrough discovery could lead to earlier diagnosis and treatment of the disease.
A landmark study found a strong genetic correlation between higher education and protective causal association with several gut disorders. The research reveals that better education reduces the risk of diseases such as Alzheimer's and inflammatory bowel disease (IBD).
A new nanopore-based sensing device explores the aggregation of tau and tubulin proteins in neurodegenerative diseases such as Alzheimer's and Parkinson's. The device provides volume information about protein molecules and their states at the single-molecule level, offering insights into protein binding and aggregation.
Researchers have discovered a possible cause of neurodegeneration in the early stages of Alzheimer's disease using fruit flies. The study found that an overabundance of the TOMM40 gene causes marked cell death in the retina, which corresponds to the level of protein produced by the gene.
Researchers at UT Health San Antonio identified a new inflammatory trigger in Alzheimer's disease and progressive supranuclear palsy, involving 'jumping genes' that form double-stranded RNA mimicking viral infections. This discovery opens new doors for understanding astrocyte biology and their role in transposable element control.
A new USC study found that the buildup of amyloid beta protein in the brain is not directly linked to Alzheimer's disease, but rather a general change associated with aging. Researchers discovered higher levels of soluble Aβ protein in healthy brains, while insoluble fibrillary amyloid was more closely tied to poor brain health.
A team of researchers led by Adrian Oblak and Peter Bor-Chian Lin studied the INPP5D gene, which is associated with microglia-specific immune cells. They found that reducing its expression can mitigate Alzheimer's disease pathology, preserving cognitive function in lab models.
Researchers have identified a previously unknown component of brain anatomy, dubbed SLYM, which acts as a protective barrier and immune monitoring platform. The discovery is expected to shed light on the glymphatic system's mechanisms and its potential role in brain diseases like Alzheimer's.
Researchers found that neurons in the hippocampus represent space in a nonlinear hyperbolic geometry that grows outward exponentially with time spent exploring an environment. This discovery provides valuable methods for analyzing data on neurocognitive disorders involving learning and memory.
Researchers examined associations between APOE ε2 and ε4 alleles, polygenic profiles, and Alzheimer's disease biomarkers. They found links between ε4 alleles with plasma and CSF Aβ42 and CSF tau, as well as differences in associations with tau and Aβ42.
MIT scientists use single-cell profiling to analyze the cellular function of brain cells affected by Alzheimer's disease, identifying five main areas of disruption. The study reveals specific molecular programs and gene regulation changes that could lead to valuable biomarkers and therapeutic interventions.
A new biomarker test, called BD-tau, can detect Alzheimer's disease neurodegeneration in blood samples with high accuracy. The test outperforms current methods and correlates well with CSF biomarkers, providing a valuable tool for improved diagnosis and clinical trial design.
Researchers identified six genes associated with dementia risk in people of African ancestry, differing from those found in European populations. The study highlights the need for increased representation of non-European ancestry groups in genetic research to address health disparities.
Researchers at Drexel University used GPT-3 to spot early signs of Alzheimer's in spontaneous speech, achieving 80% accuracy. The program analyzed word-use, sentence structure and meaning from transcripts to identify characteristic profiles of Alzheimer's speech.
A digital detection of dementia study aims to evaluate the practical use of an AI tool for early identification of Alzheimer's disease and related dementias. The study uses a passive digital marker and patient-reported outcomes survey, which have shown potential in detecting mild cognitive impairment and reducing healthcare costs.
A recent study has identified common and unique cellular processes in six neurodegenerative diseases, providing new insights into the underlying causes of these conditions. The research used machine learning analysis to compare RNA markers in whole blood samples from patients with distinct diseases, revealing eight shared themes across...
A study reveals that big dynorphin, an endogenous opioid peptide, protects neurons against β-amyloid accumulation. The research suggests that big dynorphin can hinder the interaction between β-amyloid and form aggregates, promoting a neuroprotective effect.
A retrospective cohort study of 28,311 COVID-19 patients in Germany found a significant association between dementia and increased risk of death. The association was weaker than previously reported studies, suggesting potential changes in the impact of dementia on COVID-19 mortality over time.
A recent study from the University of Eastern Finland suggests that previous traumatic brain injury may increase the risk of frontotemporal dementia (FTD), particularly in individuals without a genetic mutation. Patients who suffered head injuries developed FTD earlier than others, on average.
A UCI-led study reveals that outbred Chilean degu rodents exhibit robust neurodegenerative features, including hippocampal neuronal loss and altered parvalbumin staining, resembling human Alzheimer's Disease. This provides a practical model for studying sporadic AD.
Columbia University's Vagelos College of Physicians and Surgeons has launched a neurodegenerative disease research center, thanks to a $50 million gift from the Carol and Gene Ludwig Family Foundation. The Center will support research on Alzheimer's disease and related disorders, with a focus on innovative treatments.
A recent study suggests that stimulating the intersection of two particular brain networks correlated with better patient outcomes than stimulating nearby sites for patients with Alzheimer's disease. Cognitive improvement was associated with DBS to the direct interface between the fornix and bed nucleus of the stria terminalis.
Researchers discovered a modified form of an inflammatory immune protein called complement C3 that is present at higher levels in women's brains with Alzheimer's compared to men's. This finding may explain why women are more likely to develop the disease, as estrogen levels drop during menopause and lose their brain-protective effects.
Researchers from IIT have discovered a correlation between small RNA molecules, piRNAs, and brain inflammation. The study lays the groundwork for new diagnostic technologies to detect neurodegenerative diseases, such as Alzheimer's and Parkinson's, at an early stage.
Researchers discovered a brain network that reduces Alzheimer's symptoms when stimulated, paving the way for further studies. A small group of participants benefited from deep brain stimulation, with the optimal stimulation site located at the intersection of two fiber bundles connecting regions deep in the brain.
Researchers tested three widely believed aging treatments in mice and found no impact on aging. A new analytical approach allowed them to measure aging processes more precisely, revealing that these treatments promote general health rather than targeting aging mechanisms.
A Northwestern University study found that as people age, their cerebrospinal fluid immune system becomes dysregulated, leading to cognitive impairment and neurodegeneration. The discovery provides a new clue to the process of neurodegeneration and may potentially be used to treat inflammation of the brain.
A study funded by NIH found that people with Down syndrome have a similar level of amyloid plaques in their brains as those with hereditary, early-onset Alzheimer's. This suggests that individuals with both conditions may benefit from participating in studies on Alzheimer's therapies aimed at slowing amyloid plaque formation.
Researchers aim to reduce disparities in dementia diagnosis and treatment with a 5-minute screening tool. The study will enroll 6,600 participants in urban and rural communities.
A study published by Tufts University has found a link between higher levels of vitamin D in brain tissue and improved cognitive function in adults. The research, which analyzed brain tissue from over 200 participants, suggests that vitamin D may play a role in protecting the aging brain against diseases such as Alzheimer's.
A recent study published in Molecular Psychiatry reveals a genetic link between attention-deficit/hyperactivity disorder (ADHD) and Alzheimer's disease in older adults. Researchers used a polygenic risk score to analyze the relationship between ADHD genetic predisposition and cognitive decline, finding a higher risk of developing Alzhe...
A study aims to enhance accessibility and value of health information tools for older adults with both diabetes and Alzheimer's disease. The research focuses on developing a user-friendly technology to detect low blood sugar, which can cause dizziness, confusion, and even death.
A new study found that impaired glymphatic system function is associated with Alzheimer's disease progression. Noninvasive MRI measures of the glymphatic system's volume and diffusivity were linked to amyloid beta deposition, neuronal damage, and cognitive impairment in patients with Alzheimer's.
A novel peptide has been developed to selectively detect and neutralize an early molecular trigger of Alzheimer's disease. The technology allows for the detection of the disease at all stages, including presymptomatic cases, with high sensitivity and specificity.
A new laboratory test can measure levels of amyloid beta oligomers in blood samples, detecting toxic proteins up to years before cognitive impairment. The test, SOBA, has shown promising results in identifying individuals at risk or incubating Alzheimer's disease.
Scientists have developed an AI method to pinpoint cells indicative of Alzheimer's disease based on DNA packing in mouse brain images, offering a potential early detection tool. This approach combines multi-scale imaging with artificial intelligence to identify biomarkers for aging-related diseases.
Researchers have discovered that a specific mutation in the misfolding protein causing Parkinson's disease can also protect against multiple system atrophy (MSA), another fatal neurodegenerative disorder. The findings provide a promising lead for developing targeted treatments using personalized medicine approaches.
Researchers from the Salk Institute have found that deteriorating neurons from people with Alzheimer's disease undergo a late-life stress process called senescence, leading to brain inflammation and neurodegeneration. By targeting these senescent cells with therapeutics, scientists hope to prevent or treat Alzheimer's disease.
Researchers from University of Cologne and Technical University of Munich discovered that the signal peptidase complex plays a crucial role in quality control of membrane proteins. The complex cleaves faulty membrane proteins to initiate their degradation, maintaining cellular function. This discovery has important implications for und...
Researchers have identified optimal blood tests to detect Alzheimer's disease at its earliest stages. The study found that phospho-tau217 is a reliable marker for monitoring disease progression and selecting individuals for novel trials.
Early stage clinical studies confirm 40Hz sensory stimulation is safe, with no serious adverse effects. The therapy also showed significant neurological and behavioral benefits, including improved brain activity, reduced brain atrophy, and better sleep patterns.
Researchers identified formic acid as a sensitive urinary biomarker for early-stage Alzheimer's disease, which could lead to large-scale screening programs. The study found that formic acid levels correlate with cognitive decline and can predict disease stage when combined with blood-based biomarkers.
Researchers identify INPP5D as a key player in the inflammation process contributing to Alzheimer's disease, which may offer new potential targets for therapies. The study found that mice with inactivated INPP5D gene had more plaques covered by microglia, suggesting unexpected results when modulating inflammation genes.
Researchers found that a gene mutation in mice resulted in increased plaque deposits and larger clumps, suggesting the gene plays a critical role in immune defenses. The study may lead to new therapies targeting this gene mutation to slow progression of Alzheimer's disease.
A team of Oregon State University scientists used biophysical techniques to study the malfunctioning motor protein dynein, which is associated with neurodegenerative diseases like ALS and Alzheimer's. The study sheds light on how dynein's transport machinery fails in these disorders, leading to the accumulation of misfolded proteins.
Researchers at Lund University have discovered that activating the TREM2 receptor on microglial cells slows down Alzheimer's disease progression by clearing tau protein aggregates. This innovative approach may lead to a new treatment method for Alzheimer's disease, in addition to reducing beta-amyloid and tau proteins.
A Rutgers study suggests that mucosal-associated invariant T cells (MAITs) protect against cognitive decline by creating antioxidant molecules. Injecting MAITs into genetically altered mice restored their cognitive function, and researchers hope to compare MAIT numbers in healthy humans and those with cognitive diseases like Alzheimer's.
A survey by UCI MIND found that news coverage of the FDA's decision made the public less willing to volunteer for Alzheimer's pharmaceutical trials. The study suggests that media attention can have a significant impact on people's choices, potentially hindering scientific progress. Researchers plan to conduct further research to better...
A Cornell-led collaboration used machine learning to predict Alzheimer's progression in cognitively normal and mildly impaired individuals. The modeling showed that MRI scans are most informative for asymptomatic cases, while PET scans are more effective for those with mild cognitive impairment.
Researchers at UC San Diego School of Medicine identified PKCα as a potential therapeutic target for Alzheimer's disease. The study found that a subtle increase in PKCα activity was sufficient to produce biochemical, cellular and cognitive impairments in mice, similar to those observed in human AD.
A new biomarker has been identified with up to 89% accuracy for corticobasal degeneration, a primary tauopathy. The discovery could accelerate progress toward therapies for this rare brain disease, which is often misdiagnosed due to similar symptoms.
A study at the University of Gothenburg discovered a unique quick-closing valve in the aquaporins of climbing perch fish, allowing them to rapidly regulate water in their cells. This finding could lead to the development of new drugs for cancer and Alzheimer's disease by understanding how brain cell aquaporins function.
A systematic review article collects 30 years of protein research data to provide a detailed GPS system for Alzheimer's disease research. The study highlights the involvement of the VPS10p-domain receptor family in brain degeneration and cell-to-cell communication, providing new insights into the disease's development.
A recent study reveals that Down syndrome brains develop the same amyloid beta and tau prions as Alzheimer's disease, causing neurological dysfunction. With over 50% of people with Down syndrome developing Alzheimer's by age 40, this discovery offers new insights into the common underlying causes of these two diseases.
Researchers from Indiana University School of Medicine identified the protein bassoon as a key contributor to tau neurotoxicity in Alzheimer's disease. The study found that bassoon stabilizes the tau seed, allowing it to propagate in the brain and exacerbate neurodegeneration.
A new study published in the journal Nature has identified medin as a key player in Alzheimer's therapies. Medin, a protein that accumulates in the blood vessels of the brain, promotes vascular pathology and cognitive decline. The researchers hope to develop a treatment targeting medin to prevent vascular damage and cognitive decline.